Selected article for: "drug therapy and MERS coronavirus"
Author: Zhand, Sareh; Saghaeian Jazi, Marie; Mohammadi, Saeed; Tarighati Rasekhi, Roozbeh; Rostamian, Ghassem; Kalani, Mohammad Reza; Rostamian, Aida; George, Jacob; Douglas, Mark W
Title: COVID-19: The Immune Responses and Clinical Therapy Candidates
  • Cord-id: kaglnlok
  • Document date: 2020_8_3
    • ID: kaglnlok
    Snippet: The pandemic of coronavirus disease 2019 (COVID-19), with rising numbers of patients worldwide, presents an urgent need for effective treatments. To date, there are no therapies or vaccines that are proven to be effective against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Several potential candidates or repurposed drugs are under investigation, including drugs that inhibit SARS-CoV-2 replication and block infection. The most promising therapy to date is remdesivir, which is US
    Document: The pandemic of coronavirus disease 2019 (COVID-19), with rising numbers of patients worldwide, presents an urgent need for effective treatments. To date, there are no therapies or vaccines that are proven to be effective against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Several potential candidates or repurposed drugs are under investigation, including drugs that inhibit SARS-CoV-2 replication and block infection. The most promising therapy to date is remdesivir, which is US Food and Drug Administration (FDA) approved for emergency use in adults and children hospitalized with severe suspected or laboratory-confirmed COVID-19. Herein we summarize the general features of SARS-CoV-2’s molecular and immune pathogenesis and discuss available pharmacological strategies, based on our present understanding of SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV) infections. Finally, we outline clinical trials currently in progress to investigate the efficacy of potential therapies for COVID-19.

    Search related documents:
    Co phrase search for related documents
    • aberrant activation and activation result: 1, 2, 3, 4
    • aberrant activation and acute inflammation: 1
    • aberrant activation and acute respiratory distress syndrome: 1, 2
    • aberrant activation and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • accessory protein and action mechanism: 1
    • accessory protein and activator kinase signal transducer: 1
    • accessory protein and acute respiratory distress syndrome: 1, 2, 3
    • accessory protein and acute respiratory distress syndrome develop: 1
    • accessory protein and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acid analogue and acute respiratory syndrome: 1
    • action different mechanism and acute respiratory distress syndrome: 1
    • action different mechanism and acute respiratory syndrome: 1, 2, 3, 4, 5, 6
    • action include and acute respiratory syndrome: 1, 2, 3, 4, 5
    • action mechanism and acute inflammation: 1, 2, 3, 4
    • action mechanism and acute respiratory distress syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
    • action mechanism and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • action site and acute inflammation: 1
    • action site and acute respiratory syndrome: 1, 2, 3, 4
    • activation result and acute inflammation: 1, 2